Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-upTwo biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for Share XNeurocrine and Xenon agree $1.75bn epilepsy R&D tie-uphttps://pharmaphorum.com/news/neurocrine-and-xenon-agree-1-75bn-epilepsy-rd-tie-up/
Neurocrine slumps as Tourette’s drug fails clinical trialShares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed Share XNeurocrine slumps as Tourette’s drug fails clinical trialhttps://pharmaphorum.com/news/neurocrine-slumps-as-tourettes-drug-fails-clinical-trial/
